» Articles » PMID: 19474567

The Alzheimer's Disease Centers' Uniform Data Set (UDS): the Neuropsychologic Test Battery

Abstract

The neuropsychologic test battery from the Uniform Data Set (UDS) of the Alzheimer's Disease Centers (ADC) program of the National Institute on Aging consists of brief measures of attention, processing speed, executive function, episodic memory, and language. This paper describes development of the battery and preliminary data from the initial UDS evaluation of 3268 clinically cognitively normal men and women collected over the first 24 months of utilization. The subjects represent a sample of community-dwelling, individuals who volunteer for studies of cognitive aging. Subjects were considered "clinically cognitively normal" based on clinical assessment, including the Clinical Dementia Rating scale and the Functional Assessment Questionnaire. The results demonstrate performance on tests sensitive to cognitive aging and to the early stages of Alzheimer disease in a relatively well-educated sample. Regression models investigating the impact of age, education, and sex on test scores indicate that these variables will need to be incorporated in subsequent normative studies. Future plans include: (1) determining the psychometric properties of the battery; (2) establishing normative data, including norms for different ethnic minority groups; and (3) conducting longitudinal studies on cognitively normal subjects, individuals with mild cognitive impairment, and individuals with Alzheimer disease and other forms of dementia.

Citing Articles

GWAS links to neuropsychiatric symptoms in mild cognitive impairment and dementia.

Vattathil S, Blostein F, Miller-Fleming T, Davis L, Wingo T, Wingo A medRxiv. 2025; .

PMID: 39974048 PMC: 11838693. DOI: 10.1101/2025.01.31.25321498.


Tau Burden is Best Captured by Magnitude and Extent: Tau-MaX as a Measure of Global Tau.

Brown C, Das S, Cousins K, Tropea T, Plotkin A, Detre J medRxiv. 2025; .

PMID: 39867392 PMC: 11759618. DOI: 10.1101/2025.01.13.25320488.


Association of Alzheimer's and Lewy body disease pathology with basal forebrain volume and cognitive impairment.

Schumacher J, Teipel S, Storch A Alzheimers Res Ther. 2025; 17(1):28.

PMID: 39865328 PMC: 11771035. DOI: 10.1186/s13195-025-01678-x.


Sex differences in mitochondrial free-carnitine levels in subjects at-risk and with Alzheimer's disease in two independent study cohorts.

Bigio B, Lima-Filho R, Barnhill O, Sudo F, Drummond C, Assuncao N Mol Psychiatry. 2025; .

PMID: 39774493 DOI: 10.1038/s41380-024-02862-5.


TOMM40 may mediate GFAP, neurofilament light Protein, pTau181, and brain morphometry in aging.

Honea R, Wilkins H, Hunt S, Kueck P, Burns J, Swerdlow R Aging Brain. 2025; 7:100134.

PMID: 39760103 PMC: 11699468. DOI: 10.1016/j.nbas.2024.100134.


References
1.
Guillozet A, Weintraub S, Mash D, Marsel Mesulam M . Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003; 60(5):729-36. DOI: 10.1001/archneur.60.5.729. View

2.
Albert M . Memory decline: the boundary between aging and age-related disease. Ann Neurol. 2002; 51(3):282-4. View

3.
Reed B, Mungas D, Kramer J, Ellis W, Vinters H, Zarow C . Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain. 2007; 130(Pt 3):731-9. DOI: 10.1093/brain/awl385. View

4.
Elias M, Beiser A, Wolf P, Au R, White R, DAgostino R . The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000; 57(6):808-13. DOI: 10.1001/archneur.57.6.808. View

5.
Rentz D, Huh T, Faust R, Budson A, Scinto L, Sperling R . Use of IQ-adjusted norms to predict progressive cognitive decline in highly intelligent older individuals. Neuropsychology. 2004; 18(1):38-49. DOI: 10.1037/0894-4105.18.1.38. View